ClinicalTrials.gg

Program

zanubrutinib

Also written as “Zanubrutinib”, “BGB-3111” and “BGB-3111 and Drug Cocktail”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, B-Cell, Marginal Zone, led by BeOne Medicines.

Furthest: phase 4, since Sep 5, 202535 company-led studies, 8 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines358 open or runningphase 4since Sep 5, 2025Jan 9, 2015Dec 31, 2026phase 3 · NCT04170283

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Jan 9, 2015.

  1. Nov 18, 2019Phase 3 study in B-cell MalignanciesNCT04170283 · 955 enrolled · United States, Australia, China and more
  2. May 7, 2020Phase 2 study in COVID-19NCT04382586 · 63 enrolled · United States
  3. Jun 16, 2020Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04436107 · 66 enrolled · China
  4. Jul 10, 2020Phase 1 study in HealthyNCT04470908 · 13 enrolled · United States
  5. Sep 9, 2020Phase 1 study in B-cell MalignanciesNCT04551963 · 26 enrolled · Australia
  6. Nov 18, 2020Phase 2 study in Lupus NephritisNCT04643470 · 177 enrolled · China
  7. Sep 27, 2021Phase 3 study in Lymphoma, FollicularNCT05100862 · 799 enrolled · United States, Argentina, Australia and more
  8. Sep 27, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05068440 · 65 enrolled · China
  9. Sep 16, 2022Phase 1 study in Healthy VolunteersNCT05547399 · 43 enrolled · United States
  10. Jan 23, 2023Phase 3 study in Primary Membranous NephropathyNCT05707377 · 178 enrolled · United States, Brazil, Canada and more
  11. Mar 2, 2023Phase 1 study in Healthy VolunteersNCT05767398 · 58 enrolled · United States
  12. Oct 3, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06073821 · 652 enrolled · United States, Australia, Austria and more
  13. Sep 5, 2025Phase 4 study in Waldenstrom MacroglobulinemiaNCT07169331 · 16 enrolled · China
  14. Dec 2, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07277231 · 500 planned · United States, Australia, Brazil and more

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in B-cell MalignanciesNCT04170283
  2. Oct 2027Primary completion: phase 3 study in Primary Membranous NephropathyNCT05707377
  3. Jul 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT05100862
  4. Oct 31, 2028Primary completion: phase 4 study in Waldenstrom MacroglobulinemiaNCT07169331

TargetBeta

BTK →read by rule
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07277231Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more3RecruitingFeb 2031500
NCT07169331Waldenstrom Macroglobulinemia · China4Active, not recruitingOct 31, 202816
NCT06073821Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingFeb 2032652
NCT05767398Healthy Volunteers · United States1CompletedApr 28, 202358
NCT05707377Primary Membranous Nephropathy · United States, Brazil, Canada and more3Active, not recruitingOct 2027178
NCT05547399Healthy Volunteers · United States1CompletedDec 7, 202243
NCT05100862Lymphoma, Follicular · United States, Argentina, Australia and more3Active, not recruitingJul 2028799
NCT05068440Lymphoma, Large B-Cell, Diffuse · China2CompletedMar 31, 202565
NCT04643470Lupus Nephritis · China2CompletedFeb 26, 2024177
NCT04551963B-cell Malignancies · Australia1CompletedFeb 21, 202226
NCT04470908Healthy · United States1CompletedNov 10, 202013
NCT04436107Lymphoma, Large B-Cell, Diffuse · China1CompletedMar 28, 202466
NCT04382586COVID-19 · United States2CompletedFeb 1, 202163
NCT04170283B-cell Malignancies · United States, Australia, China and more3Active, not recruitingDec 31, 2026955
NCT04172246Leukemia, Lymphocytic, Chronic, B-Cell · Japan2CompletedMay 10, 202355
NCT04163783Healthy Volunteers · United States1CompletedApr 18, 20176
NCT04163523Healthy Volunteers · Australia1CompletedJul 21, 201618
NCT04116437Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedJan 9, 202696
NCT04002297Lymphoma, Mantle-Cell · United States, Australia, Austria and more3Active, not recruitingApr 27, 2026510
NCT03734016Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedAug 8, 2022652
NCT03846427Lymphoma, B-Cell, Marginal Zone · United States, Australia, China and more2CompletedMay 4, 202268
NCT03561298Healthy Subjects · United States1CompletedJun 7, 201818
NCT03520920Lymphoma, B-Cell, Marginal Zone · China2CompletedAug 28, 202041
NCT03465059Hepatic Insufficiency · United States1CompletedOct 19, 201829
NCT03432884Healthy Volunteers · United States1CompletedApr 16, 201840
NCT03332173Waldenstrom Macroglobulinemia · China2CompletedMay 8, 201944
NCT03336333Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingMay 7, 2021590
NCT03301181Healthy Volunteers: Asian, Non-Asian · United States1CompletedNov 7, 201740
NCT03206970Lymphoma, Mantle-Cell · China2CompletedFeb 15, 201986
NCT03206918Recurrence · China2CompletedJun 15, 201891
NCT03189524Lymphoma, B-Cell · China1CompletedAug 26, 202044
NCT03145064Lymphoma, Large B-Cell, Diffuse · China2CompletedMay 24, 201941
NCT02795182Lymphoma · Australia, China1CompletedDec 18, 202075
NCT02569476Lymphoma · United States, Australia, Korea, Republic of1CompletedSep 2, 2020119
NCT02343120B-cell Malignancies · United States, Australia, Italy and more2CompletedMar 31, 2021385

How it is read

Names in the registry

  • “Zanubrutinib”, 30 entries
  • “BGB-3111”, 2 entries
  • “zanubrutinib”, 1 entry
  • “BGB-3111 and Drug Cocktail”, 1 entry
  • “BGB-3111 (Arm A)”, 1 entry

Codes read as this program: BGB3111.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.